| Current and emerging pharmacotherapies for obesity in Australia. | Obes Res Clin Pract | 2017 Sep - Oct | 28818558 |
| Topiramate-Induced Lithium Toxicity. | Cureus | 2017 Oct 26 | 29308332 |
| Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. | Curr Diab Rep | 2017 May | 28378293 |
| Pathophysiological targets for non-pharmacological treatment of migraine. | Cephalalgia | 2016 Oct | 26637237 |
| Topiramate Extended Release: A Review in Epilepsy. | CNS Drugs | 2016 Jun | 27224993 |
| Antimuscarinic-induced convulsions in fasted animals after food intake:evaluation of the effects of levetiracetam, topiramate and different doses ofatropine. | Naunyn Schmiedebergs Arch Pharmacol | 2016 Jan | 26453200 |
| Meal replacements followed by topiramate for the treatment of adolescent severeobesity: A pilot randomized controlled trial. | Obesity (Silver Spring) | 2016 Dec | 27807925 |
| A low TSH profile predicts olanzapine-induced weight gain and relief byadjunctive topiramate in healthy male volunteers. | Psychoneuroendocrinology | 2016 Apr | 26802597 |
| Clinical utility of topiramate extended-release capsules (USL255): Bioequivalenceof USL255 sprinkled and intact capsule in healthy adults and an in vitroevaluation of sprinkle delivery via enteral feeding tubes. | Epilepsy Behav | 2016 Apr | 26943947 |
| Ability of Food/Drink to Reduce the Bitterness Intensity of Topiramate asDetermined by Taste Sensor Analysis. | Chem Pharm Bull (Tokyo) | 2016 | 26726740 |